Predicting Risk of Mortality in Lung Cancer Patients for Improved Clinical Trials and Patient Access
The costs associated with every cancer patient recruited into a clinical trial are enormously high. Improving clinical trials and finding ways to design them with greater speed and efficiency has become mission critical for life sciences companies.
Real-World Data Enables Study of ICIs in Patients Frequently Excluded from Traditional Clinical Trials
Patients with evidence of autoimmune disease are frequently excludedfrom clinical trials for new immuno-oncology drugs. An innovative research collaboration between ASCO and the FDA sought to better understand the outcomes of patients with evidence of autoimmune diseases being treated with immune checkpoint inhibitors (ICIs) in real world settings.
The changing needs of cancer patients require new approaches to clinical drug development. Any significant change and transformation will need true convergence and collaboration across new digital data sources, powerful computing and AI technologies and regulatory authorities.
The ability to expand clinical trial eligibility criteria quickly and efficiently is becoming a critical aspect of clinical trial design, to maximize the number of patients who can participate and benefit from new and experimental drugs and to increase the generalizability of study findings.